Cargando…

Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data

Colorectal cancer (CRC) is one of the most frequent tumours and one of the major causes of morbidity and mortality globally. Its incidence has increased in recent years and could be linked to unhealthy dietary habits combined with environmental and hereditary factors, which can lead to genetic and e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sardo, Emilia, Napolitano, Stefania, Della Corte, Carminia Maria, Ciardiello, Davide, Raucci, Antonio, Arrichiello, Gianluca, Troiani, Teresa, Ciardiello, Fortunato, Martinelli, Erika, Martini, Giulia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880341/ https://www.ncbi.nlm.nih.gov/pubmed/35207616 http://dx.doi.org/10.3390/jpm12020128

Ejemplares similares

Beyond N staging in colorectal cancer: Current approaches and future perspectives
por: Arrichiello, Gianluca, et al.
Publicado: (2022)

Present and future of metastatic colorectal cancer treatment: A review of new candidate targets
por: Martini, Giulia, et al.
Publicado: (2017)

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
por: Troiani, Teresa, et al.
Publicado: (2016)

Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer
por: Caputo, Vincenza, et al.
Publicado: (2023)

Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells
por: Napolitano, Stefania, et al.
Publicado: (2017)

Towards the era of precision medicine in metastatic colorectal cancer
por: Napolitano, Stefania, et al.
Publicado: (2020)

Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation
por: Napolitano, Stefania, et al.
Publicado: (2017)

Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the COVID-19 Pandemic
por: Napolitano, Stefania, et al.
Publicado: (2022)

Implication of the Hedgehog pathway in hepatocellular carcinoma
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)

Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer
por: Arrichiello, Gianluca, et al.
Publicado: (2022)

Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review
por: Fasano, Morena, et al.
Publicado: (2022)

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
por: Napolitano, Stefania, et al.
Publicado: (2022)

Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
por: Vitiello, Pietro Paolo, et al.
Publicado: (2021)

Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines
por: Vitiello, Pietro Paolo, et al.
Publicado: (2019)

Role and targeting of anaplastic lymphoma kinase in cancer
por: Della Corte, Carminia Maria, et al.
Publicado: (2018)

Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series
por: Guerrera, Luigi Pio, et al.
Publicado: (2022)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
por: Ciardiello, Davide, et al.
Publicado: (2021)

Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial
por: Martini, Giulia, et al.
Publicado: (2023)

How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma
por: Martini, Giulia, et al.
Publicado: (2021)

Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAF(V600E)-Mutant Colorectal Cancer
por: Napolitano, Stefania, et al.
Publicado: (2023)

Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941
por: Ciardiello, Davide, et al.
Publicado: (2022)

Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab
por: Martini, Giulia, et al.
Publicado: (2022)

Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care
por: Martinelli, Erika, et al.
Publicado: (2007)

Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
por: Ciardiello, Davide, et al.
Publicado: (2021)

Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype
por: Ciardiello, Davide, et al.
Publicado: (2021)

Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience
por: Caputo, Vincenza, et al.
Publicado: (2022)

Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial
por: Della Corte, Carminia Maria, et al.
Publicado: (2022)

Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
por: Napolitano, Stefania, et al.
Publicado: (2023)

Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)

Correction: Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Corte, Carminia Maria Della, et al.
Publicado: (2022)

Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials
por: Ciardiello, Davide, et al.
Publicado: (2023)

Mechanisms of resistance to EGFR-targeted drugs: lung cancer
por: Morgillo, Floriana, et al.
Publicado: (2016)

Kisspeptin and Cancer: Molecular Interaction, Biological Functions, and Future Perspectives
por: Ciaramella, Vincenza, et al.
Publicado: (2018)

How we treat metastatic colorectal cancer
por: De Falco, Vincenzo, et al.
Publicado: (2020)

AXL is an oncotarget in human colorectal cancer
por: Martinelli, Erika, et al.
Publicado: (2015)

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC
por: Della Corte, Carminia Maria, et al.
Publicado: (2022)

Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models
por: Belli, Valentina, et al.
Publicado: (2019)

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
por: Martinelli, Erika, et al.
Publicado: (2018)

Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience
por: Vitiello, Pietro Paolo, et al.
Publicado: (2019)

Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy
por: Fasano, Morena, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ns8bmnb5e2u1vgmjlqf2ce2r0c